Candidemia Diagnosed
Blood culture positive for Candida species
All Pathways
Infectious DiseaseManagement
Candidemia & Invasive Candidiasis Management (IDSA 2016)
Candidemia & Invasive Candidiasis Management (IDSA 2016): Candidemia Diagnosed → Initial Management → Empiric Antifungal Therapy → Candida Species Ident...
Pathway Overview
14 steps
Algorithm Steps
14 total
01Start 02Action Initial Management
Start antifungal immediately
- Remove all central venous catheters
- Repeat blood cultures daily until negative
- Dilated ophthalmologic exam
- Echo if prolonged candidemia or valve disease
03Action Empiric Antifungal Therapy
Echinocandin first-line
- Caspofungin 70mg load, then 50mg daily, OR
- Micafungin 100mg daily, OR
- Anidulafungin 200mg load, then 100mg daily
- Fluconazole alternative if low resistance risk
04Decision Candida Species Identification
Critical for de-escalation
05Action C. albicans (Most Common)
Usually fluconazole-susceptible
- If stable and susceptible: Can de-escalate to Fluconazole 400mg daily
- Continue echinocandin if critically ill
06Action Source Control
Essential for cure
- Remove all CVCs - do NOT attempt salvage
- Drain abscesses
- Evaluate for deep-seated infection: Eye, heart, kidney, liver, spleen
07Action Ophthalmologic Exam
Within first week
- Chorioretinitis in 5-15%
- If positive: Intravitreal antifungal + systemic
- Longer duration of therapy needed
08Action Duration of Therapy
14 days minimum from negative culture
- Uncomplicated: 14 days from first negative culture
- Endocarditis: 6 weeks after valve surgery
- Eye involvement: 4-6 weeks
- Deep-seated: Individualized
09Outcome Resolved
Negative cultures, completed therapy
10Warning Complications
Endophthalmitis, endocarditis, metastatic
11Action Echocardiogram
If risk factors
- Persistent candidemia >72h
- Prior valve disease, prosthetic valve
- IVDU
- TTE first; TEE if high suspicion
- Path rejoins step 08Shared downstream outcome
12Action C. glabrata
Often fluconazole-resistant
- Continue echinocandin
- Await susceptibilities before considering azole
- High-dose fluconazole 800mg if susceptible
- Path rejoins step 06Shared downstream outcome
13Action C. krusei
Intrinsically fluconazole-resistant
- Continue echinocandin
- Voriconazole alternative if needed
- Path rejoins step 06Shared downstream outcome
14Warning C. auris
Multi-drug resistant, infection control alert
- Often resistant to fluconazole and echinocandins
- Use echinocandin initially; await susceptibilities
- Amphotericin B if echinocandin-resistant
- Contact precautions, notify infection control
- Path rejoins step 06Shared downstream outcome
Guideline Source
IDSA Clinical Practice Guidelines for the Management of Candidiasis 2016
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- ⚠️ UNVALIDATED DRAFT: This algorithm was AI-generated from guideline summaries and has NOT been reviewed by clinical experts. All doses, thresholds, and pathways MUST be verified against primary sources by qualified clinicians before clinical use. Do not use for patient care without expert validation.
- Species identification critical for therapy
- Echinocandin resistance emerging
- Line removal essential
- Eye exam mandatory
Applicable Regions
USEU
Version 1Next review: 2027-01-11
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Candidemia & Invasive Candidiasis Management (IDSA 2016)?
The Candidemia & Invasive Candidiasis Management (IDSA 2016) is a management clinical algorithm for Infectious Disease. It provides a structured decision tree to guide clinical decision-making, based on IDSA Clinical Practice Guidelines for the Management of Candidiasis 2016.
What guideline is the Candidemia & Invasive Candidiasis Management (IDSA 2016) based on?
This algorithm is based on IDSA Clinical Practice Guidelines for the Management of Candidiasis 2016 (DOI: 10.1093/cid/civ933).
What are the limitations of the Candidemia & Invasive Candidiasis Management (IDSA 2016)?
Known limitations include: ⚠️ UNVALIDATED DRAFT: This algorithm was AI-generated from guideline summaries and has NOT been reviewed by clinical experts. All doses, thresholds, and pathways MUST be verified against primary sources by qualified clinicians before clinical use. Do not use for patient care without expert validation.; Species identification critical for therapy; Echinocandin resistance emerging; Line removal essential; Eye exam mandatory. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Candidemia & Invasive Candidiasis Management (IDSA 2016) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free